- Home
- BBAI vs ELVN Comparison
BBAI vs ELVN Comparison
Compare BBAI & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAI
- ELVN
- Stock Information
- Founded
- BBAI 2020
- ELVN 2016
- Country
- BBAI United States
- ELVN United States
- Employees
- BBAI N/A
- ELVN N/A
- Industry
- BBAI EDP Services
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- BBAI Technology
- ELVN Health Care
- Exchange
- BBAI Nasdaq
- ELVN Nasdaq
- Market Cap
- BBAI 1.1B
- ELVN 1.0B
- IPO Year
- BBAI N/A
- ELVN 2020
- Fundamental
- Price
- BBAI $4.89
- ELVN $21.60
- Analyst Decision
- BBAI Buy
- ELVN Strong Buy
- Analyst Count
- BBAI 4
- ELVN 5
- Target Price
- BBAI $4.50
- ELVN $37.80
- AVG Volume (30 Days)
- BBAI 33.3M
- ELVN 269.1K
- Earning Date
- BBAI 03-06-2025
- ELVN 03-13-2025
- Dividend Yield
- BBAI N/A
- ELVN N/A
- EPS Growth
- BBAI N/A
- ELVN N/A
- EPS
- BBAI N/A
- ELVN N/A
- Revenue
- BBAI $154,972,000.00
- ELVN N/A
- Revenue This Year
- BBAI $13.47
- ELVN N/A
- Revenue Next Year
- BBAI $16.32
- ELVN N/A
- P/E Ratio
- BBAI N/A
- ELVN N/A
- Revenue Growth
- BBAI 0.01
- ELVN N/A
- 52 Week Low
- BBAI $1.17
- ELVN $10.90
- 52 Week High
- BBAI $5.20
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- BBAI 57.03
- ELVN 47.03
- Support Level
- BBAI $3.52
- ELVN $20.40
- Resistance Level
- BBAI $4.53
- ELVN $22.42
- Average True Range (ATR)
- BBAI 0.43
- ELVN 1.25
- MACD
- BBAI -0.01
- ELVN 0.06
- Stochastic Oscillator
- BBAI 67.80
- ELVN 59.59
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.